SEC Form 4 · accession 0000899243-16-025288
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John N Bonfiglio
Officer — See Remarks · Director
Period of report
Jul 18, 2016
Accepted (ET)
Jul 19, 2016 · 2:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 15, 2016 | A | 250,000 | $0.00 | A | 250,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $0.475 | Jul 18, 2016 | A | 750,000 | A | — | Jul 18, 2026 | Common Stock | 750,000 | 1,150,000 | D |
Explanation of responses
- F1Represents restricted stock award under the Company's 2014 Omnibus Stock Ownership Plan (the "Plan") granted in connection with the execution of employment agreement with the Company. The shares vest upon the earlier to occur of (i) the listing of the Company's common stock on a national securities exchange and (ii) the first anniversary of the grant date, or July 18, 2017, so long as recipient is employed with the Company.
- F2Represents option awarded under the Plan in connection with the execution of employment agreement with the Company. Of the 750,000 option shares awarded, 250,000 shares vest immediately, and the remaining options vest in 23 equal monthly installments of 20,833 shares, and the remaining 20,841 shares vest on the last day of the 24th month. The option exercise price is the closing price on July 15, 2016 the trading day immediately prior to the award date.
Remarks
President and Chief Operating Officer